Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study

Acta Psychiatrica Scandinavica

Volumn 95, Issue 1, 1997, Pages 40-43

  Rossi, A ^a   Mancini, F ^a   Stratta, P ^a   Mattel, P ^a   Gismondi, R ^b   Pozzi, F ^b   Casacchia, M ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Janssen Cilag SpA Italia   (Italy)

Author keywords

cognitive deficit; negative symptoms; risperidone; schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031042376     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb00371.x     Document Type: Article

References (21)

1. OPLER LA, ALBERT D, RAMIREZ PM. Psychopharmacologic treatment of negative schizophrenic symptoms. Compr Psychiatry 1994: 35: 16-28.
2. HIRSCH SR. Clinical treatment of schizophrenia. In: BRADLEY PB, HIRSH SR, ed. The psychopharmacology and treatment of schizophrenia. New York: Oxford University Press, 1986.
3. KRAEPELIN E. Dementia praecox and paraphrenia. Edinburgh: Churchill Livingstone, 1919.
4. GOLDBERG TE, GOLD JM. Neurocognitive functioning in patients with schizophrenia: an overview. In: BLOOM FE, KUPFER DJ, ed. Psychopharmacology: the fourth generation in progress. New York: Raven Press, 1995: 1245-1257.
5. OWENS DGC. Extrapyramidal side-effects and tolerability of risperidone: a review. J Clin Psychiatry 1994: 55 (Suppl. 5): 29-35.
6. PICKAR D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995: 345: 557-562.
7. GOLDBERG TE, GREENBERG RD, GRIFFIN SJ et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993: 162: 43-48.
8. LEYSEN JE, GOMMEREN W, EENS A et al. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988: 247: 661-670.
9. 2 antagonistic properties. J Pharmacol Exp Ther 1988: 244: 685-693.
10. GERLACH J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991: 17: 289-309.
11. BLEICH A, BROWN SL, KAHN R et al. The role of serotonin in schizophrenia. Schizophr Bull 1988: 14: 297-315.
12. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989: 25: 390-392.
13. MELTZER HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991: 17: 263-287.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd edn. Washington, DC: American Psychiatric Association, 1987.
15. KAY SR, FIZBEIN A, OPLER LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987: 13: 261-276.
16. HEATON RK. Wisconsin Card Sorting Test manual. Odessa: Psychological Assessment Resources, 1981.
17. WECHSLER D. WAIS-R manual. New York: Psychological Corporation, 1981.
18. LEE MA, THOMPSON PA, MELTZER HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994: 55 (Suppl. B): 82-87.
19. SALETU B, GRUNBERGER J, KINZAMAYER L et al. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmacoEEG and psychometry. Pharmacopsychiatry 1987: 20: 12-27.
20. GOLDBERG TE, WEINBERGER DR. The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994: 55 (Suppl. B): 88-90.
21. DANIEL DG. Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders (abstract). Biol Psychiatry 1994: 35: 667.